Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alcoholic-energy settlement

This article was originally published in The Tan Sheet

Executive Summary

MillerCoors Brewing Co. agrees to stop marketing products containing caffeine, guarana, ginseng and taurine in a Dec. 18 settlement with San Francisco and 13 states - Arizona, California, Connecticut, Idaho, Illinois, Iowa, Maine, Maryland, Mississippi, New Mexico, New York, Ohio and Oklahoma. The city and the states alleged the firm made false or misleading health-related statements about the energizing effects of a Sparks beer product and that much of the marketing was directed at youth. The agreement comes six months after Anheuser-Busch made a similar settlement concerning its alcoholic-energy drinks (1"The Tan Sheet" June 30, 2008, In Brief)

MillerCoors Brewing Co. agrees to stop marketing products containing caffeine, guarana, ginseng and taurine in a Dec. 18 settlement with San Francisco and 13 states - Arizona, California, Connecticut, Idaho, Illinois, Iowa, Maine, Maryland, Mississippi, New Mexico, New York, Ohio and Oklahoma. The city and the states alleged the firm made false or misleading health-related statements about the energizing effects of a Sparks beer product and that much of the marketing was directed at youth. The agreement comes six months after Anheuser-Busch made a similar settlement concerning its alcoholic-energy drinks (1 'The Tan Sheet' June 30, 2008, In Brief).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel